newsfilter
← Latest News
GlobeNewswire·

SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference

MIAMI, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SAB BIO (NASDAQ:SABS) (the "Company" or "SAB"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin